Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF FINANCIAL OFFICER | January 26, 2026 | January 29, 2026 |
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | CFO and Treasurer | January 22, 2021 | January 26, 2021 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date January 26, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,521 |
Reported balance
After 2026-01-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-26 · Sale · Disposed 3,746 · Balance 24,521 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing.
INTERCEPT PHARMACEUTICALS, INC.
Report date January 22, 2021 · Filed January 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,964 |
Reported balance
After 2021-01-22 transaction · row 1
1 source rowRow 1 · 2021-01-22 · Grant · Acquired 17,200 · Balance 40,964 F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2031-01-22 | Direct | 26,900 |
Reported balance
After 2021-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-22 · Grant · Acquired 26,900 · Balance 26,900 F2: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021.
F2: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 20:12 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 10,539 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001677141-26-000006 · form4-05212026_080513.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,539 Underlying: Common Stock · 10,539 shares Expires 2036-05-19 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| January 26, 2026 Filed Jan 29, 2026 01:19 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 3,746 | $37.15 | $139,171.39 |
DisclosureSEC source: 0001677141-26-000004 · form4-01292026_010123.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,521 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 4,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · derivative · entry 8 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,175 Underlying: Common Stock · 4,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_price: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.expiration_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 2,553 | $36.82 | $94,001.46 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · nonDerivative · entry 4 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,172 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 4,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · nonDerivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 3,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · derivative · entry 7 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,625 Underlying: Common Stock · 3,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 2,239 | $36.82 | $82,439.98 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,574 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 3,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · derivative · entry 6 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 Underlying: Common Stock · 12,200 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:49 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 42,600 | $0.00 Strike: $36.76 | $0.00 |
DisclosureSEC source: 0001677141-26-000002 · form4-01262026_090157.xml · derivative · entry 5 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,600 Underlying: Common Stock · 42,600 shares Expires 2036-01-22 F2 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:39 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 20,961 | $35.92 | $752,833.18 |
DisclosureSEC source: 0001677141-26-000001 · form4-01212026_010111.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001677141-25-000008 · form4-12092025_041201.xml · derivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 20,000 shares Expires 2031-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option shall vest with respect to 50% of the underlying shares on March 23, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on April 23, 2023. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 20,000 | $39.54 | $790,896.00 |
DisclosureSEC source: 0001677141-25-000008 · form4-12092025_041201.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.63. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 20,000 | $29.03 | $580,600.00 |
DisclosureSEC source: 0001677141-25-000008 · form4-12092025_041201.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 3,427 | $35.00 | $119,945.00 |
DisclosureSEC source: 0001677141-25-000006 · form4-11252025_041102.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001677141-25-000004 · form4-10022025_041003.xml · derivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 24,039 | $27.56 | $662,514.84 |
DisclosureSEC source: 0001677141-25-000004 · form4-10022025_041003.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,961 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001677141-25-000004 · form4-10022025_041003.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 21,573 | $36.50 | $787,377.83 |
DisclosureSEC source: 0001415889-25-022294 · form4-08192025_040801.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.11 to $36.87. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2025 Filed May 31, 2025 01:41 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 201,857 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-25-015077 · form4-05312025_010556.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,857 Underlying: Common Stock · 201,857 shares Expires 2035-05-28 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 740 | $33.12 | $24,505.25 |
DisclosureSEC source: 0001415889-25-009936 · form4-04032025_040408.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.02 to $33.22. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 6,247 | $32.48 | $202,880.70 |
DisclosureSEC source: 0001415889-25-009936 · form4-04032025_040408.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 740 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $33.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 29, 2025 Filed Apr 1, 2025 20:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009357 · form4-04012025_040402.xml · derivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023. 25% of the underlying shares are scheduled to vest on each of March 29, 2024 and March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023. 25% of the underlying shares are scheduled to vest on each of March 29, 2024 and March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023. 25% of the underlying shares are scheduled to vest on each of March 29, 2024 and March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| March 29, 2025 Filed Apr 1, 2025 20:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 8,014 | $33.19 | $265,984.66 |
DisclosureSEC source: 0001415889-25-009357 · form4-04012025_040402.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,986 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| March 29, 2025 Filed Apr 1, 2025 20:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009357 · form4-04012025_040402.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 28, 2025 21:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,775 | $38.05 | $67,547.27 |
DisclosureSEC source: 0001415889-25-002158 · form4-01282025_090140.xml · nonDerivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.68. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 21:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 18,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002158 · form4-01282025_090140.xml · derivative · entry 6 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires not disclosed F6 · derivative.exercise_price: . The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F6 · derivative.exercise_date: . The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F6 · derivative.expiration_date: . The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 21:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 66,250 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0001415889-25-002158 · form4-01282025_090140.xml · derivative · entry 5 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,250 Underlying: Common Stock · 66,250 shares Expires 2035-01-25 F5 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 25, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 3,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002158 · form4-01282025_090140.xml · derivative · entry 4 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,438 Underlying: Common Stock · 3,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 2,037 | $38.01 | $77,426.37 |
DisclosureSEC source: 0001415889-25-002158 · form4-01282025_090140.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,775 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 3,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002158 · form4-01282025_090140.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001415889-25-001925 · form4-01232025_090105.xml · derivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 25,000 shares Expires 2031-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option shall vest with respect to 50% of the underlying shares on March 23, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on April 23, 2023. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 25,000 | $40.18 | $1,004,597.50 |
DisclosureSEC source: 0001415889-25-001925 · form4-01232025_090105.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.53. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 25,000 | $29.03 | $725,750.00 |
DisclosureSEC source: 0001415889-25-001925 · form4-01232025_090105.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024357 · form4-10022024_081004.xml · derivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This award of restricted stock units was previously granted on October 4, 2023. 40% of the underlying shares vested on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: This award of restricted stock units was previously granted on October 4, 2023. 40% of the underlying shares vested on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: This award of restricted stock units was previously granted on October 4, 2023. 40% of the underlying shares vested on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 32,052 | $40.00 | $1,282,080.00 |
DisclosureSEC source: 0001415889-24-024357 · form4-10022024_081004.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,948 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024357 · form4-10022024_081004.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:55 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 47,693 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001415889-24-014312 · form4-05232024_080500.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,693 Underlying: Common Stock · 47,693 shares Expires 2034-05-21 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009781 · form4-04022024_040442.xml · derivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023 and 25% of the shares vested on March 29, 2024, with the remaining 25% of the underlying shares scheduled to vest on March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023 and 25% of the shares vested on March 29, 2024, with the remaining 25% of the underlying shares scheduled to vest on March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023 and 25% of the shares vested on March 29, 2024, with the remaining 25% of the underlying shares scheduled to vest on March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 8,013 | $33.58 | $269,076.54 |
DisclosureSEC source: 0001415889-24-009781 · form4-04022024_040442.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,987 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009781 · form4-04022024_040442.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:53 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 15,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001869 · form4-01262024_090119.xml · derivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:53 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 74,250 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0001415889-24-001869 · form4-01262024_090119.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,250 Underlying: Common Stock · 74,250 shares Expires 2034-01-24 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| October 04, 2023 Filed Nov 8, 2023 21:00 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 Strike: $31.78 | $0.00 |
DisclosureSEC source: 0001415889-23-014888 · form4-11082023_091127.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F1 · derivative.expiration_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032565 · doc4.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005668 · form4-03312023_080303.xml · derivative · entry 3 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023. 25% of the underlying shares are scheduled to vest on each of March 29, 2024 and March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023. 25% of the underlying shares are scheduled to vest on each of March 29, 2024 and March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: This award of restricted stock units was previously granted on March 29, 2021. 50% of the underlying shares vested on March 29, 2023. 25% of the underlying shares are scheduled to vest on each of March 29, 2024 and March 29, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 15,414 | $33.36 | $514,211.04 |
DisclosureSEC source: 0001415889-23-005668 · form4-03312023_080303.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,586 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005668 · form4-03312023_080303.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:14 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 5,000 | $1.19 | $5,964.50 |
DisclosureSEC source: 0001209191-22-059462 · doc4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:28 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-22-032825 · doc4.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.